Indeed, co-targeting of SHP2 using SHP099 and FGFR using FIIN4 inhibitor was shown to decrease primary tumor and metastatic outgrowth in HER2-enriched and TNBC models. The gene discussed is PTPN11; the disease is neoplasm.